Abstract 6119
Background
Cancer nursing is required to identify potential advances in nursing practice, assess their relevance for ones own particular clinical situation, gather opinion on any potential change in practice (both locally and farther afield), integrate this into practice, evaluate success and then disseminate the learning from this process. Until relatively recently this process could be reasonably laborious and slow moving. However, the advent of social media sites and software and their use in nursing has streamlined this process making the gathering, group analysis and dissemination of clinical information faster and more intuitive. This study considers the authors own experience in using two social media sites (Twitter and Facebook) to gather and share clinical infomation as part of the UK Oncology Nursing Society and when setting up a new Members Interest Group for UK Lead Cancer Nurses.
Methods
This piece describes the use of Twitter and Facebook group as a professional tool to -: 1) Gather cancer nursing opinion on a particular subject (case study - Streamlining MDT Working in England and the contrubution of specialist Nursing) - potentially a ’digitall Delphi Technique’ using Twitter and Facebook 2) Build group cohesion, ask clinical questions, share information and practice and build relationships within a newly established UK group of Lead Cancer Nurses. The experiences of UKONS members of using social media professionally will be gathered, the clinical effectivenes of using social media to gather nursing opinion on a particular nursing problem (streamlining MDT working) will be analysed.
Results
The experiences of cancer nurses in using social media in professional settings will be presented as part of an overall narrative and key themes will be presented and discussed Number and range of responses to a clinical question posed on social media will be presented with consideration of how effective a tool Twitter is in gathering clinical opinion and driving improvement. Ths will be presented numerically and graphically.
Conclusions
The positive impact of the professional use of social media will be presented. Potential uses and fine tuning of these tools in cancer nursing will be considered Potential pitfalls and negative effects will also be considered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract